Clinical efficacy and immunomodulatory mechanism of budesonide nasal spray combined with mucus promoter in patients with chronic sinusitis

Chronic rhinosinusitis (CR) seriously affects the patient’s life quality, and current clinical treatment faces certain challenges. This study observed the effects of budesonide nasal spray combined with mucus promoter on the clinical efficacy and immunomodulatory mechanism of CR patients. 105 patients with CR from Zhejiang Xin'an International Hospital between January 2021 and January 2024 were categorized into EL group and BE group, both groups underwent mucus promoter intervention and BE group were added with budesonide nasal spray intervention. Inflammatory and immunity indicators (CD4+ and CD8+ Tcells percentage) and clinical efficacy were mainly assessed. Secondary results included Lund-Kenndey score, Lund-Mackey score, nasal ventilation function [DCAN, NCV, NMCA, and nasal airway resistance], clinical symptom scores, adverse effects incidences, and recurrence rates. After treatment, the indicators of the both groups were superior to pre-treatment (P<0.05). The CD4+ Tcells percentage, CD4+/CD8+, NCV, NMCA, clinical symptom scores and clinical efficacy in BE group were markedly above the EL group, and inflammatory indicators, CD8+ Tcells percentage, Lund-Kenndey score, Lund-Mackey score, DCAN, nasal airway resistance, adverse effects incidences and recurrence rate were markedly below the EL group (P<0.05). This combined therapy has a remarkable curative effect, which is worthy of popularizing and use in the clinic.